Europe’s attempts to contain its escalating coronavirus outbreak appeared to be faltering, as Germany became the latest country to warn that it was on the verge of an epidemic.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the t hird fully funded collaboration ...

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Full Year 2019 Financial & Operational Results Dyadic International Inc. (NASDAQ: DYAI) released full year 2019 financial and operational results on March 30, 2020. Revenues were $1.7 million and represented research and development proceeds from partners working to develop C1. Total expenses were $11.0 million and net

JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying ...

JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2020 after the market close on Thursday, May 14, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. To access the replay which will expire May 28, 2020, dial 1 (877) 481-4010 (U.S. or Canada) or 1 (919) 882-2331 (International) and enter replay pass code: 34441. Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.

JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.

Q1 2020 Dyadic International Inc Earnings Call

NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit ...

JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP). The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd ("VTT") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. "Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Anne Huuskonen, VTT Senior Scientist.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.

JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Contract Development and Manufacturing Organization (CDMO). Under the terms of the research license agreement, Dyadic will grant WuXi Biologics restricted access to its proprietary and patented C1 gene expression platform and allow WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform certain experiments to the C1 cell lines for any other internal noncommercial purpose.

Two fully funded research projects with top four animal health companies. Nonexclusive research license agreement with WuXi Biologics. Feasibility study with the University of Oslo on influenza vaccine. ...

JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. (NASDAQ:DYAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at ...

NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats. IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).

JUPITER, FL / ACCESSWIRE / April 20 , 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving and applying ...

Q4 2019 Dyadic International Inc Earnings Call

Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...